Re: How to achieve international action on falsified and substandard medicines

Article Highlights

  • Many of the most glaring problems of the WHO's pre-qualification program were resolved more than 5 years ago.

    Tweet This

  • A global treat to improve medicine quality does not depend, fortunately, on the WHO's enforcement capability.

    Tweet This

  • There is a pressing need for an international treaty to mitigate the problem of substandard drugs

    Tweet This

Subscribe to AEI's health emails
Articles and events on health policy. Published approximately twice a month.

First Name:
Last Name:
Email:
Zip Code:

Jerry Norris raises the important issue of the oversight of drug quality and the role of the World Health Organisation’s pre-qualification program (WHO PQ). He is correct that WHO PQ had significant problems early on, but teething problems were resolved more than 5 years ago, and his observations today seem dated and irrational.

"WHO -prequalified malaria medicines, while not always perfect, are significantly less likely to be substandard than their competitors." -Roger Bate and Amir AttaranFor example, Mr. Norris complains that when in 2004 WHO discovered low quality medicines being sold as prequalified, it withdrew its prequalification. That actually seems reasonable to us—or would Mr. Norris rather the alternative that WHO sweep the problem under the rug and not withdraw its prequalification?

Mr. Norris implies that because WHO is ineffectual, so would be a global treaty to improve medicine quality. That is a wild leap of illogic, and simply wrong. First, a global treaty would cover far more products than just the small number of WHO-prequalified medicines. Second, a treaty would not depend on WHO for its enforcement mechanisms (indeed, WHO is not a law enforcement agency). Third, in the limited role it plays today, WHO has achieved much to improve medicine quality. As we have shown elsewhere (http://www.dovepress.com/articles.php?article_id=10449) WHO-prequalified malaria medicines, while not always perfect, are significantly less likely to be substandard than their competitors.

We agree with Mr. Norris when he concedes that WHO processes can help bring about “a substantial mitigation of substandard drugs.” The pressing need now is for an international law mandate—basically, a treaty—to prioritize that task, not just for WHO, but for all its member states.

Roger Bate is a resident scholar at the American Enterprise Institute.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate

What's new on AEI

Rebuilding American defense: A speech by Governor Bobby Jindal
image Smelling liberal, thinking conservative
image Stopping Ebola before it turns into a pandemic
image All too many reasons for pessimism about Europe
AEI on Facebook
Events Calendar
  • 20
    MON
  • 21
    TUE
  • 22
    WED
  • 23
    THU
  • 24
    FRI
Monday, October 20, 2014 | 2:00 p.m. – 3:30 p.m.
Warfare beneath the waves: The undersea domain in Asia

We welcome you to join us for a panel discussion of the undersea military competition occurring in Asia and what it means for the United States and its allies.

Tuesday, October 21, 2014 | 8:30 a.m. – 10:00 a.m.
AEI Election Watch 2014: What will happen and why it matters

AEI’s Election Watch is back! Please join us for two sessions of the longest-running election program in Washington, DC. 

Wednesday, October 22, 2014 | 1:00 p.m. – 2:30 p.m.
What now for the Common Core?

We welcome you to join us at AEI for a discussion of what’s next for the Common Core.

Thursday, October 23, 2014 | 10:00 a.m. – 11:00 a.m.
Brazil’s presidential election: Real challenges, real choices

Please join AEI for a discussion examining each candidate’s platform and prospects for victory and the impact that a possible shift toward free-market policies in Brazil might have on South America as a whole.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.